The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

Gene editing involves precise changes in DNA sequences using enzymes, revolutionizing medical, agricultural, and research ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

received the National Medal of Technology and Innovation in recognition of his work developing the revolutionary gene-editing ...

Researchers have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal neurodegenerative condition. The treatment, which uses ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...

Jennifer Doudna, a UC Berkeley biochemist who shared the 2020 Nobel Prize in Chemistry for the invention of CRISPR-Cas9 ...